NCT00003465View on ClinicalTrials.gov

Temozolomide in Treating Patients With Anaplastic Oligodendroglioma

PHASE2CompletedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

March 31, 1998

Study Completion Date

February 28, 2001

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG

temozolomide

Trial Locations (1)

27710

Duke Comprehensive Cancer Center, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Duke University

OTHER

NCT00003465 - Temozolomide in Treating Patients With Anaplastic Oligodendroglioma | Biotech Hunter | Biotech Hunter